Take Homes in Psoriasis

Take Homes in Psoriasis

Source: Reich K, et al. Bimekizumab efficacy and safety versus secukinumab in patients with moderate to severe plaque psoriasis: Results from a multicenter, randomized, double-blinded, active comparator-controlled phase 3b trial (BE RADIANT). Presented at: AAD VMX 2021; April 23-25, 2021 (Virtual).
Disclosures: Gelfand reports consulting for Bristol Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Lilly (DMC), Janssen Biologics, Novartis Corp, UCB (DSMB) and receiving honoraria; receiving research grants (to the Trustees of the University of Pennsylvania) from AbbVie, Boehringer Ingelheim, Janssen, Novartis Corp, Amgen, and Pfizer Inc.; being deputy editor for the Journal of Investigative Dermatology, receiving honoraria from the Society for Investigative Dermatology; and being a member of the board of directors for the International Psoriasis Council, receiving no honoraria.
May 22, 2021
2 min watch
Save

VIDEO: Bimekizumab a 'major advantage' for skin clearance in psoriasis

Source: Reich K, et al. Bimekizumab efficacy and safety versus secukinumab in patients with moderate to severe plaque psoriasis: Results from a multicenter, randomized, double-blinded, active comparator-controlled phase 3b trial (BE RADIANT). Presented at: AAD VMX 2021; April 23-25, 2021 (Virtual).
Disclosures: Gelfand reports consulting for Bristol Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Lilly (DMC), Janssen Biologics, Novartis Corp, UCB (DSMB) and receiving honoraria; receiving research grants (to the Trustees of the University of Pennsylvania) from AbbVie, Boehringer Ingelheim, Janssen, Novartis Corp, Amgen, and Pfizer Inc.; being deputy editor for the Journal of Investigative Dermatology, receiving honoraria from the Society for Investigative Dermatology; and being a member of the board of directors for the International Psoriasis Council, receiving no honoraria.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this video, Joel M. Gelfand, MD, MSCE, professor of dermatology and epidemiology at the University of Pennsylvania Perelman School of Medicine, discussed results from a recent study evaluating bimekizumab in patients with plaque psoriasis.

The study, BE RADIANT, was among the late-breaking research presented at AAD VMX 2021.

Gelfand said that more patients who received bimekizumab achieved Psoriasis Area and Severity Index 100 at 16 weeks and skin clearance at 48 weeks compared with those who received Cosentyx (secukinumab, Novartis).

“This is a major advantage in our treatment of psoriasis, in terms of the ability to clear people at such a high rate,” Gelfand said.

However, he noted that patients in the bimekizumab group were more likely to develop fungal infection than those in the secukinumab group.

Due to this finding, Gelfand said that “clinicians and patients will need to decide if the extra benefit you receive from clearing your psoriasis [is] worth the risk for mild nuisance skin infections,” noting that the infections observed among patients included in the study were typically not serious enough to lead to discontinuation.